Cencora, Inc. (NYSE:COR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Fourteen analysts give Cencora a "Moderate Buy" (12 buys, 2 holds) with a 12‑month average price target of $403.17, and several firms (JPMorgan, Barclays, Evercore) recently raised targets or reiterated positive ratings.
• Quarterly results and valuation: Cencora beat EPS expectations ($4.08 vs. $4.04) but missed revenue estimates slightly ($85.93B vs. $86.12B); the stock trades at about a 39x PE, market cap ~$63.2B, and pays a $0.60 quarterly dividend (0.7% yield).
• Insider and institutional activity: CEO Robert P. Mauch sold 5,096 shares (~$1.81M), reducing his holding by 7.1%, while institutional investors own roughly 97.5% of the company.

Shares of Cencora, Inc. (NYSE:COR - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $403.1667.

Several brokerages have recently weighed in on COR. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded shares of Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, February 5th. Evercore restated an "outperform" rating on shares of Cencora in a research report on Tuesday, March 17th. Barclays boosted their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. Finally, Robert W. Baird set a $415.00 price objective on shares of Cencora in a research report on Tuesday, January 13th.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,096 shares of the company's stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is currently owned by company insiders.

Institutional Trading of Cencora

Several institutional investors and hedge funds have recently bought and sold shares of COR. Kemnay Advisory Services Inc. purchased a new stake in Cencora in the 4th quarter valued at $25,000. Oakworth Capital Inc. purchased a new stake in Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in Cencora in the 4th quarter valued at $27,000. Archer Investment Corp raised its position in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company's stock valued at $28,000 after purchasing an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in Cencora in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Trading Up 1.3%

NYSE COR opened at $324.91 on Thursday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. Cencora has a 52 week low of $269.37 and a 52 week high of $377.54. The stock has a market capitalization of $63.20 billion, a PE ratio of 39.05, a price-to-earnings-growth ratio of 1.51 and a beta of 0.72. The firm has a 50 day moving average of $346.71 and a two-hundred day moving average of $342.23.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm's revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.73 EPS. As a group, research analysts expect that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora's payout ratio is currently 28.85%.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.